Evolocumab
Brand names: Repatha Syringe, Repatha Pushtronex, Repatha Sureclick
At a glance
- Medicare prescriptions, 2024
- 1,856,832
- Medicare drug cost
- $1.59B
- Average cost per prescription
- $858
- Clinicians who prescribed it
- 39,313
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events. As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Cardiology 39.7%
- Interventional Cardiology 15.0%
- Nurse Practitioners 14.0%
- Internal Medicine 11.2%
- Family Medicine 9.1%
- Physician Assistants 5.2%
- Endocrinology & Diabetes 1.9%
- Cardiac Electrophysiology 0.7%
- Heart Failure & Transplant Cardiology 0.6%
- Nephrology (Kidney) 0.4%
- Nuclear Medicine 0.4%
- Pharmacists 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 491% from 2019 to 2024.
Biggest change by state since 2019
- North Carolina +749%
- Pennsylvania +602%
- Louisiana +600%
- Ohio +538%
- Virginia +518%
- California (smallest change) +319%
- New Jersey (smallest change) +347%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $6.9M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Amgen Inc. $6.9M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.